Hu-rhEGF-rP64k/Mont

DB15781InvestigationalVaccines

Hu-rhEGF-rP64k/Mont is a vaccine used to prevent recurrence of certain lung cancers in patients who have already received cyclophosphamide. Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the treatment of advanced non-small cell lung cancer...

What you can answer from here — as of April 02, 2025

1Structured indicationCondition, population, route and combination as fields, not prose

8ContraindicationsEach with its own population and attribute set

1Marketed productAcross every region we cover

1+ReferenceStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Hu-rhEGF-rP64k/Mont, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account